Quantitative sensory testing and pain-evoked cytokine reactivity

Comparison of patients with sickle cell disease to healthy matched controls

Claudia Campbell, Christopher P Carroll, Kasey Kiley, Dingfen Han, Carlton Haywood, Sophie Lanzkron, Lauren Swedberg, Robert R. Edwards, Gayle G. Page, Jennifer Haythornthwaite

Research output: Contribution to journalArticle

Abstract

Sickle cell disease (SCD) is an inherited blood disorder associated with significant morbidity, which includes severe episodic pain, and, often, chronic pain. Compared to healthy individuals, patients with SCD report enhanced sensitivity to thermal detection and pain thresholds and have altered inflammatory profiles, yet no studies to date have examined biomarker reactivity after laboratory-induced pain. We sought to examine this relationship in patients with SCD compared to healthy control participants. We completed quantitative sensory testing in 83 patients with SCD and sequential blood sampling in 27 of them, whom we matched (sex, age, race, body mass index, and education) to 27 healthy controls. Surprisingly, few quantitative sensory testing differences emerged between groups. Heat pain tolerance, pressure pain threshold at the trapezius, thumb, and quadriceps, and thermal temporal summation at 45°C differed between groups in the expected direction, whereas conditioned pain modulation and pain ratings to hot water hand immersion were counterintuitive, possibly because of tailoring the water temperature to a perceptual level; patients with SCD received milder temperatures. In the matched subsample, group differences and group-by-time interactions were observed in biomarkers including tumor necrosis factor alpha, interleukin-1β, interleukin-4, and neuropeptide Y. These findings highlight the utility of laboratory pain testing methods for understanding individual differences in inflammatory cytokines. Our findings suggest amplified pain-evoked proinflammatory cytokine reactivity among patients with SCD relative to carefully matched controls. Future research is warranted to evaluate the impact of enhanced pain-related cytokine response and whether it is predictive of clinical characteristics and the frequency/severity of pain crises in patients with SCD.

Original languageEnglish (US)
Pages (from-to)949-956
Number of pages8
JournalPain
Volume157
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Sickle Cell Anemia
Cytokines
Pain
Pain Threshold
Hot Temperature
Biomarkers
Temperature
Superficial Back Muscles
Water
Neuropeptide Y
Thumb
Immersion
Interleukin-1
Individuality
Chronic Pain
Interleukin-4
Healthy Volunteers
Body Mass Index
Research Design
Hand

Keywords

  • central sensitization
  • clinical pain
  • cytokines
  • inflammation
  • laboratory pain
  • QST
  • Sickle cell disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine
  • Neurology
  • Pharmacology

Cite this

Quantitative sensory testing and pain-evoked cytokine reactivity : Comparison of patients with sickle cell disease to healthy matched controls. / Campbell, Claudia; Carroll, Christopher P; Kiley, Kasey; Han, Dingfen; Haywood, Carlton; Lanzkron, Sophie; Swedberg, Lauren; Edwards, Robert R.; Page, Gayle G.; Haythornthwaite, Jennifer.

In: Pain, Vol. 157, No. 4, 01.04.2016, p. 949-956.

Research output: Contribution to journalArticle

@article{35156c9fe69242deaa33a18b9708a7cb,
title = "Quantitative sensory testing and pain-evoked cytokine reactivity: Comparison of patients with sickle cell disease to healthy matched controls",
abstract = "Sickle cell disease (SCD) is an inherited blood disorder associated with significant morbidity, which includes severe episodic pain, and, often, chronic pain. Compared to healthy individuals, patients with SCD report enhanced sensitivity to thermal detection and pain thresholds and have altered inflammatory profiles, yet no studies to date have examined biomarker reactivity after laboratory-induced pain. We sought to examine this relationship in patients with SCD compared to healthy control participants. We completed quantitative sensory testing in 83 patients with SCD and sequential blood sampling in 27 of them, whom we matched (sex, age, race, body mass index, and education) to 27 healthy controls. Surprisingly, few quantitative sensory testing differences emerged between groups. Heat pain tolerance, pressure pain threshold at the trapezius, thumb, and quadriceps, and thermal temporal summation at 45°C differed between groups in the expected direction, whereas conditioned pain modulation and pain ratings to hot water hand immersion were counterintuitive, possibly because of tailoring the water temperature to a perceptual level; patients with SCD received milder temperatures. In the matched subsample, group differences and group-by-time interactions were observed in biomarkers including tumor necrosis factor alpha, interleukin-1β, interleukin-4, and neuropeptide Y. These findings highlight the utility of laboratory pain testing methods for understanding individual differences in inflammatory cytokines. Our findings suggest amplified pain-evoked proinflammatory cytokine reactivity among patients with SCD relative to carefully matched controls. Future research is warranted to evaluate the impact of enhanced pain-related cytokine response and whether it is predictive of clinical characteristics and the frequency/severity of pain crises in patients with SCD.",
keywords = "central sensitization, clinical pain, cytokines, inflammation, laboratory pain, QST, Sickle cell disease",
author = "Claudia Campbell and Carroll, {Christopher P} and Kasey Kiley and Dingfen Han and Carlton Haywood and Sophie Lanzkron and Lauren Swedberg and Edwards, {Robert R.} and Page, {Gayle G.} and Jennifer Haythornthwaite",
year = "2016",
month = "4",
day = "1",
doi = "10.1097/j.pain.0000000000000473",
language = "English (US)",
volume = "157",
pages = "949--956",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Quantitative sensory testing and pain-evoked cytokine reactivity

T2 - Comparison of patients with sickle cell disease to healthy matched controls

AU - Campbell, Claudia

AU - Carroll, Christopher P

AU - Kiley, Kasey

AU - Han, Dingfen

AU - Haywood, Carlton

AU - Lanzkron, Sophie

AU - Swedberg, Lauren

AU - Edwards, Robert R.

AU - Page, Gayle G.

AU - Haythornthwaite, Jennifer

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Sickle cell disease (SCD) is an inherited blood disorder associated with significant morbidity, which includes severe episodic pain, and, often, chronic pain. Compared to healthy individuals, patients with SCD report enhanced sensitivity to thermal detection and pain thresholds and have altered inflammatory profiles, yet no studies to date have examined biomarker reactivity after laboratory-induced pain. We sought to examine this relationship in patients with SCD compared to healthy control participants. We completed quantitative sensory testing in 83 patients with SCD and sequential blood sampling in 27 of them, whom we matched (sex, age, race, body mass index, and education) to 27 healthy controls. Surprisingly, few quantitative sensory testing differences emerged between groups. Heat pain tolerance, pressure pain threshold at the trapezius, thumb, and quadriceps, and thermal temporal summation at 45°C differed between groups in the expected direction, whereas conditioned pain modulation and pain ratings to hot water hand immersion were counterintuitive, possibly because of tailoring the water temperature to a perceptual level; patients with SCD received milder temperatures. In the matched subsample, group differences and group-by-time interactions were observed in biomarkers including tumor necrosis factor alpha, interleukin-1β, interleukin-4, and neuropeptide Y. These findings highlight the utility of laboratory pain testing methods for understanding individual differences in inflammatory cytokines. Our findings suggest amplified pain-evoked proinflammatory cytokine reactivity among patients with SCD relative to carefully matched controls. Future research is warranted to evaluate the impact of enhanced pain-related cytokine response and whether it is predictive of clinical characteristics and the frequency/severity of pain crises in patients with SCD.

AB - Sickle cell disease (SCD) is an inherited blood disorder associated with significant morbidity, which includes severe episodic pain, and, often, chronic pain. Compared to healthy individuals, patients with SCD report enhanced sensitivity to thermal detection and pain thresholds and have altered inflammatory profiles, yet no studies to date have examined biomarker reactivity after laboratory-induced pain. We sought to examine this relationship in patients with SCD compared to healthy control participants. We completed quantitative sensory testing in 83 patients with SCD and sequential blood sampling in 27 of them, whom we matched (sex, age, race, body mass index, and education) to 27 healthy controls. Surprisingly, few quantitative sensory testing differences emerged between groups. Heat pain tolerance, pressure pain threshold at the trapezius, thumb, and quadriceps, and thermal temporal summation at 45°C differed between groups in the expected direction, whereas conditioned pain modulation and pain ratings to hot water hand immersion were counterintuitive, possibly because of tailoring the water temperature to a perceptual level; patients with SCD received milder temperatures. In the matched subsample, group differences and group-by-time interactions were observed in biomarkers including tumor necrosis factor alpha, interleukin-1β, interleukin-4, and neuropeptide Y. These findings highlight the utility of laboratory pain testing methods for understanding individual differences in inflammatory cytokines. Our findings suggest amplified pain-evoked proinflammatory cytokine reactivity among patients with SCD relative to carefully matched controls. Future research is warranted to evaluate the impact of enhanced pain-related cytokine response and whether it is predictive of clinical characteristics and the frequency/severity of pain crises in patients with SCD.

KW - central sensitization

KW - clinical pain

KW - cytokines

KW - inflammation

KW - laboratory pain

KW - QST

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=84973345835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973345835&partnerID=8YFLogxK

U2 - 10.1097/j.pain.0000000000000473

DO - 10.1097/j.pain.0000000000000473

M3 - Article

VL - 157

SP - 949

EP - 956

JO - Pain

JF - Pain

SN - 0304-3959

IS - 4

ER -